









Markets
/
Stocks
/
nasdaq-rytm
/

Rhythm Pharmaceuticals Inc

RYTM

100.820USD

+0.610+0.61%

Close 10/10, 16:00（ET）Quotes delayed by 15 min

6.44BMarket Cap

LossP/E TTM



Rhythm Pharmaceuticals Inc

100.820

+0.610+0.61%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rhythm Pharmaceuticals Inc

Currency: USD Updated: 2025-10-09

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rhythm Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

15 / 173

Overall Ranking

52 / 4699

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 14 analysts

Buy

Current Rating

118.357

Target Price

+18.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Rhythm Pharmaceuticals Inc Highlights

StrengthsRisks

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 450.49% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 46.08.

Undervalued

The company’s latest PE is -33.31, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 67.58M shares, decreasing 3.35% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 86.55K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.07.

Financial Health

Currency: USD Updated: 2025-10-09

The company's current financial score is 8.06, which is higher than the Pharmaceuticals industry's average of 7.77. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 48.50M, representing a year-over-year increase of 66.80%, while its net profit experienced a year-over-year increase of 42.96%.

Score

Industry at a Glance

Previous score

8.06

Change



Financials

6.36

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.34

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.11

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.49

Key Metrics

Free cash flow

No Data

Rhythm Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-09

The company’s current valuation score is 7.20, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is -33.31, which is -85.51% below the recent high of -4.83 and -4.35% above the recent low of -34.75.

Score

Industry at a Glance

Previous score

7.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 15/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-09

The company’s current earnings forecast score is 8.86, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Rhythm Pharmaceuticals Inc is 115.00, with a high of 157.00 and a low of 95.00.

Score

Industry at a Glance

Previous score

8.86

Change

Support & Resistance

No Data

Analyst Rating

Based on 14 analysts

Buy

Current Rating

118.357

Target Price

+18.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

182

Total

Median

Average

Company name

Ratings

Analysts

Rhythm Pharmaceuticals Inc

RYTM

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-09

The company’s current price momentum score is 8.95, which is higher than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 104.06 and the support level at 95.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.95

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.079

Buy

RSI(14)

55.986

Neutral

STOCH(KDJ)(9,3,3)

63.011

Neutral

ATR(14)

3.245

High Vlolatility

CCI(14)

76.791

Neutral

Williams %R

29.145

Buy

TRIX(12,20)

0.035

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

99.790

Buy

MA10

99.684

Buy

MA20

98.600

Buy

MA50

98.270

Buy

MA100

85.057

Buy

MA200

70.992

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-09

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 101.74%, representing a quarter-over-quarter increase of 1.54%. The largest institutional shareholder is PRIMECAP Management, holding a total of 4.88M shares, representing 7.34% of shares outstanding, with 30.27% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

5.60M

RA Capital Management, LP

5.56M

-8.60%

PRIMECAP Management Company

Star Investors

4.88M

-15.71%

BlackRock Institutional Trust Company, N.A.

3.91M

-2.34%

The Vanguard Group, Inc.

Star Investors

3.58M

+4.20%

New Enterprise Associates (NEA)

2.91M

Perceptive Advisors LLC

2.42M

-5.11%

Fidelity Management & Research Company LLC

1.91M

+16.66%

State Street Global Advisors (US)

1.91M

-3.20%

Westfield Capital Management Company, L.P.

1.63M

+21.50%

Risk Assessment

Currency: USD Updated: 2025-10-09

The company’s current risk assessment score is 5.71, which is higher than the Pharmaceuticals industry's average of 5.11. The company's beta value is 2.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.